SuperworthKyntra Bio KYNB
- Market cap
- $18.5M
- PE
- n/m
- not a meaningful number
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- −205.2%
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $40.1M+155% | $27.1M−21% | $25.4M−30% | $998K−98% | $123K−100% | n/a | $2.7M−89% | $1.3M+35% | $1.1M+775% | n/a | $3.7M+37% | −$1.5M | |
| Cost of revenue | $4.2M−2% | $5.4M+10% | $21.3M+511% | $140K−98% | −$75K | n/a | $252K−99% | $85K−39% | −$58K−23% | n/a | $4.1M+1529% | $2K−98% |
| Gross profit | $35.9M+214% | $21.7M−26% | $4M−88% | $858K−98% | $198K−99% | n/a | $2.5M−38% | $1.3M+47% | $1.1M+473% | n/a | −$368K | −$1.5M |
| R&D | $61.2M−19% | $51.7M−16% | $36.5M−51% | $32.4M−66% | $20M−67% | n/a | $9.2M−75% | $5.9M−82% | $1.2M−94% | n/a | $7.6M−18% | $6.8M+16% |
| SG&A | $25.6M−15% | $24.2M−29% | $16.7M−51% | $14.9M−52% | $9.4M−63% | n/a | $8.1M−52% | $7.1M−53% | $5.3M−43% | n/a | $5.9M−28% | $9.3M+31% |
| −$63.5M−32% | −$54.2M−18% | −$49.2M−35% | −$46.4M−47% | −$47.7M−25% | n/a | −$14.9M−70% | −$12.1M−74% | −$5.4M−89% | n/a | −$13.8M−7% | −$17.6M+46% | |
| Interest expense | $5M+5879% | $5.1M+353% | $2.1M−12% | $1.9M−39% | $2.1M−59% | n/a | $2.3M+8% | $2M+8% | $2.1M+1% | n/a | $2.4M+8% | $2.4M+18% |
| Pre-tax income | −$64.2M−30% | −$56.8M−14% | −$49M−37% | −$47.4M−46% | −$48.3M−25% | n/a | −$16.8M−66% | −$13.8M−71% | −$13.1M−73% | n/a | −$15.1M−10% | $12M |
| $84K−26% | $80K−26% | $7K−91% | −$281K+20% | $3K−96% | n/a | $2K−71% | −$92K−67% | $0 | n/a | $0 | −$1K−99% | |
| Net income | −$63.6M−31% | −$56.2M−15% | −$32.9M−57% | −$15.5M−82% | −$17.1M−73% | $18M | $4.6M | −$7.6M−51% | $200.6M | −$14.2M | −$15.2M | $12M |
| −$16.25−34% | −$14.25−19% | −$8.25−59% | −$3.89−83% | −$4.25−74% | $4.46 | $1.15 | −$1.88−52% | $49.61 | −$3.51 | −$3.76 | $2.96 | |
| 3.9M+5% | 3.9M+5% | 4M+5% | 4M+2% | 4M+2% | 4M+2% | 4M+2% | 4M+1% | 4M+1% | 4M+0% | 4M+0% | 4M+0% |
Gross profit: 30 periods, Q3 FY18 to Q2 FY26: not printed by the filing, worked out from its own lines.
EPS, diluted: 12 periods, Q4 FY14 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 10 periods, Q4 FY14 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY18 and Q4 FY24: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Kyntra Bio's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| KYNBKyntra Bio | $18.5M | n/m | 95.0× | n/m | n/m | n/m | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| Peer median | $64.6M | 10.1× | 9.5× | 0.9× | −12% | 9.2% |
More on Kyntra Bio
Each number over time
- PE ratio
- Price to sales ratio
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .